3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Lymphoma
173
Lymphoma, Non-Hodgkin
155
Leukemia, Lymphocytic, Chronic, B-Cell
154
Lymphoma, Large B-Cell, Diffuse
134
Lymphoma, Follicular
131
Lymphoma, Mantle-Cell
93
Leukemia
68
Lymphoma, B-Cell, Marginal Zone
67
Waldenstrom Macroglobulinemia
49
Burkitt Lymphoma
43
Lymphoma, B-Cell
40
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Hodgkin Disease
36
Recurrence
24
Lymphoma, Large-Cell, Immunoblastic
24
Neoplasms
15
Myelodysplastic Syndromes
15
Lymphoma, Large-Cell, Anaplastic
15
Multiple Myeloma
13
Leukemia, Myeloid, Acute
12
Lymphoma, T-Cell, Cutaneous
9
Lymphoma, Extranodal NK-T-Cell
9
Leukemia, Hairy Cell
9
Intraocular Lymphoma
9
Hematologic Neoplasms
9
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Immunoblastic Lymphadenopathy
8
Sezary Syndrome
7
Mycosis Fungoides
7
Lymphoma, T-Cell
7
Interventions
ofatumumab
1
ocrelizumab
1
obinutuzumab
1
ibritumomab tiuxetan
1
Rituximab
1
Paclitaxel
1
Diphenhydramine
1
Cetirizine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Oncology Patients Receiving Chemotherapy
×
Rituximab
×
Clear all
NCT04189588
2023-10-06
versus
TerSera Therapeutics LLC
Phase 2
Completed
34 enrolled
11 charts